Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effectsSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Meeting (NANETS 2025), taking place October 23-25, 2025, in Aus ...

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks with high potential. On October 1, Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) and set a price target of $90.00. Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? In other news, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced the FDA approval of PALSONIFYTM (paltusotine) as a “first-line treat ...

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, November 6 at 4:30 p.m. ET Domestic:1 833-470-1428International:1 646-844-6383Access Code:166837 Webcast: Participants can use the ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), while raising the price target to $143 from $86, implying an upside potential of over 200% from the current levels. This confidence follows the company’s successful approval of Palsonify. The firm notes that Palsonify, an oral SST2 agonist designed for acromegalic adults who aren’t fit for ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $52 from $53 while keeping an Overweight rating on the shares. Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? The firm told investors that it updated Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) ...

We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the companies that soared by double- and triple-digits last week. Shares of Crinetics Pharmaceuticals climbed by 35.39 percent week-on-week as investors gobbled up shares after the Food and Drug Administration (FDA) officially approved its drug treatment for acromegaly. In a statement, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) said that it officially secured the ...

The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept. 25 transforms this clinical-stage company into a commercial powerhouse wit ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Vancouver, BC, Canada – TheNewswire - September 26, 2025 – First Tellurium Corp. (CSE: FTEL, OTCQB: FSTTF) (“First Tellurium” or the “Company”) reports that it has been requested by OTC Markets Group Inc. (“OTC Markets”) to issue this statement regarding recent promotional activity concerning the Company’s common shares traded on the OTCQB market. On September 22, 2025, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its shares, including t ...